239 related articles for article (PubMed ID: 27031960)
21. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
[TBL] [Abstract][Full Text] [Related]
22. [Effects of SIPL1 screened by suppression subtractive hybridization (SSH) on biological function and drug resistance of renal cell carcinoma cells].
Li CY; Yao AM; Chang XN; Guo YH; Xu R
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):897-903. PubMed ID: 24506958
[TBL] [Abstract][Full Text] [Related]
23. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
24. Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival.
Kim SJ; Kim KH; Ahn ER; Yoo BC; Kim SY
Amino Acids; 2013 Jan; 44(1):73-80. PubMed ID: 21960143
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition.
Jeong KC; Ahn KO; Lee BI; Lee CH; Kim SY
J Cancer Res Clin Oncol; 2010 Jan; 136(1):143-50. PubMed ID: 19655169
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
28. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
29. GTP-binding-defective forms of tissue transglutaminase trigger cell death.
Datta S; Antonyak MA; Cerione RA
Biochemistry; 2007 Dec; 46(51):14819-29. PubMed ID: 18052077
[TBL] [Abstract][Full Text] [Related]
30. Expression and activity of transglutaminase II in spontaneous tumours of dogs and cats.
Wakshlag JJ; McNeill CJ; Antonyak MA; Boehm JE; Fuji R; Balkman CE; Zgola M; Cerione RA; Page RL
J Comp Pathol; 2006; 134(2-3):202-10. PubMed ID: 16615935
[TBL] [Abstract][Full Text] [Related]
31. The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP.
Iismaa SE; Chung L; Wu MJ; Teller DC; Yee VC; Graham RM
Biochemistry; 1997 Sep; 36(39):11655-64. PubMed ID: 9305955
[TBL] [Abstract][Full Text] [Related]
32. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas.
Fukawa T; Ono M; Matsuo T; Uehara H; Miki T; Nakamura Y; Kanayama HO; Katagiri T
Cancer Res; 2012 Nov; 72(22):5867-77. PubMed ID: 23019224
[TBL] [Abstract][Full Text] [Related]
33. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance.
Zantl N; Weirich G; Zall H; Seiffert BM; Fischer SF; Kirschnek S; Hartmann C; Fritsch RM; Gillissen B; Daniel PT; Häcker G
Oncogene; 2007 Oct; 26(49):7038-48. PubMed ID: 17486061
[TBL] [Abstract][Full Text] [Related]
34. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis.
Xu Y; Diao Y; Qi S; Pan X; Wang Q; Xin Y; Cao X; Ruan J; Zhao Z; Luo L; Liu C; Yin Z
Cell Signal; 2013 May; 25(5):1176-85. PubMed ID: 23357534
[TBL] [Abstract][Full Text] [Related]
36. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
37. CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.
Min B; Park H; Lee S; Li Y; Choi JM; Lee JY; Kim J; Choi YD; Kwon YG; Lee HW; Bae SC; Yun CO; Chung KC
Oncogene; 2016 Jul; 35(28):3718-28. PubMed ID: 26568304
[TBL] [Abstract][Full Text] [Related]
38. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
Panka DJ; Liu Q; Geissler AK; Mier JW
Mol Cancer; 2013 Mar; 12():17. PubMed ID: 23497256
[TBL] [Abstract][Full Text] [Related]
39. Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9.
Ahn JS; Kim MK; Hahn JH; Park JH; Park KH; Cho BR; Park SB; Kim DJ
Biochem Biophys Res Commun; 2008 Nov; 376(4):743-7. PubMed ID: 18809380
[TBL] [Abstract][Full Text] [Related]
40. Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells.
Park KS; Han BG; Lee KH; Kim DS; Kim JM; Jeon H; Kim HS; Suh SW; Lee EH; Kim SY; Lee BI
Cancer Lett; 2009 Feb; 274(2):201-7. PubMed ID: 18851895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
